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Abstract
Background:  This study evaluated the feasibility, toxicity, response rate and survival of
neoadjuvant superselective intra-arterial infusion of high dose carboplatin in advanced head and
neck cancer.
Methods: Forty-six patients with primary head and neck squamous cell carcinoma received 3
cycles of intra-arterial carboplatin (300 to 350 mg/m2 per cycle every 2 weeks), followed by
radiotherapy or surgery plus radiotherapy.
Results: No complications or severe toxicity occurred. Sixteen patients (35%) were complete
responders, 20 (43%) partial responders while 10 (22%) did not respond to treatment. After
completion of the multimodality treatment, 38/46 patients (83%) were complete responders. After
a 5-year follow-up period, 18/46 patients (39%) are alive and disease-free, 3 (6,5%) have died of a
second primary tumor and 25 (54,5%) have died of the disease.
Conclusion: Intra-arterial carboplatin induction chemotherapy is a safe, well-tolerated technique
that discriminates between responders and non-responders and so may have prognostic
significance in planning further integrated treatments aimed to organ preservation for advanced
head and neck carcinomas.
Background
In recent years chemotherapy has become an essential
part of multimodality curative treatments for advanced
head and neck cancer, with prolongation of survival and
better organ preservation [1-3]. Several strategies have
been developed to increase the efficacy of these integrated
treatment protocols while decreasing their associated tox-
icity, e.g. induction or neoadjuvant versus concomitant
chemotherapy, intra-arterial versus intravenous systemic
administration of the drugs, single or multiple combined
chemotherapeutic agents.
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According to the detailed meta-analysis by Pignon et al.
[1], today the gold standard therapy for patients with
locally advanced head and neck squamous cell carcinoma
seems to be concurrent chemotherapy-radiation treat-
ment, with an absolute improvement of 8% in five year-
survival compared to other protocols. However, some
reports suggest that also induction chemotherapy may
improve survival, locoregional control and organ preser-
vation in oropharyngeal and laryngeal cancer [4-8].
According to Al Sarraf further advantages obtained by giv-
ing induction chemotherapy first, the incidence of sys-
temic micrometastases is reduced, the cancer is
downstaged in approximately 90% of the cases and up
50% of patients may achieve a complete clinical response
[2].
A large body of evidence supports the theoretical attrac-
tiveness of intra-arterial chemotherapy, related to the first
pass of the drug through the tumor bed and to the possi-
bility of increasing the doses of the chemotherapeutic
agent, thus minimizing systemic toxic side effects [9].
Compared to intravenous systemic chemotherapy proto-
cols, intra-arterial regimens are based on the use of a sin-
gle chemotherapeutic agent, namely cisplatin. Currently,
platinum derivatives are the most effective drugs in the
treatment of squamous cell carcinoma of the head and
neck, and the second-generation platinum drug, carbopl-
atin, possesses all of the radiopotentiation characteristics
of cisplatin with less toxic side effects [2,10].
Over recent years our group has performed a pilot study of
high-dose intra-arterial carboplatin induction chemother-
apy on patients with untreated advanced squamous cell
carcinoma of the upper aerodigestive tract. Neoadjuvant
intra-arterial chemotherapy was part of a multimodality
regimen combining radiotherapy in responder patients,
surgery plus radiotherapy in resectable non-responder
patients and palliative radiotherapy in non-resectable
non-responder patients [11]. The purpose of the present
study was to assess the feasibility and technical problems
of intra-arterial transfemoral superselective perfusion, the
maximum-tolerated dose of carboplatin, systemic and
local toxicity and the response rate after induction chem-
otherapy on the same enlarged population after a longer
term follow-up. After completing the therapeutic options
built into our multimodality protocol, we assessed five-
year overall and disease-free survival rates in patients.
Methods
Patient characteristics
Forty-six patients (43 men and 3 women), aged from 39
to 75 years (mean 58,3, median 42,1), with previously
untreated squamous cell carcinoma of the upper aerodi-
gestive tract were treated between November 1993 and
December 2000. The pre-treatment characteristics of the
patients and the site and stage of the tumour, according to
the 4th edition of the TNM used at that time [12], are
reported in table 1 and table 2. The T2 patients were sub-
mitted to this protocol owing to general conditions that
contraindicated surgery or because they refused surgery.
Table 1: Pre-treatment characteristics of the patients
Patient characteristics Number
Sex
Males 43
Females 3
Age
Range 39–75
Mean 58.3
Median 42.1
Performance status
(Karnofsky scale) > 80
Tumor stage
II 7
III 15
IV 24
Primary tumour site
Oral cavity 9
Oropharynx 28
Hypopharynx 3
Nasopharynx 1
Oral cavity + Oropharynx 4
Oropharynx + Hypopharynx 1BMC Cancer 2007, 7:62 http://www.biomedcentral.com/1471-2407/7/62
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Patients were required to sign informed consent approved
by the Ethical Committee of the Institution.
Pre-treatment evaluation
Patients underwent a complete clinical and laboratory
examination including measurement of haematologic
(complete blood cell and platelet count, prothrombin
time, partial thromboplastin time), hepatic (blood
bilirubin, transaminases and alkaline phosphatase
level)and renal (blood urea nitrogen, creatinine and elec-
trolytes level, urinanalysis, 24 hours creatinine clearance)
parameters, as well as general metabolic functions (blood
glucose and lipids level), chest radiography and cervical
vessel ultrasonography. The disease was staged by physi-
cal examination, panendoscopic examination, biopsy, CT
scan and/or MRI.
Treatment protocol
All patients received intra-arterial (i.a.) infusions of carbo-
platin, dissolved in 80 mL of 0,9% saline and infused over
10–15 min by a battery-operated pump (Medrad Mark 5
Plus) with an infusion velocity of 6–8 mL/min. An angio-
graphic catheter (Glidecath Radicofocus 5F Terumo) was
introduced percutaneously under local anesthesia (10 mL
of 2% lidocaine solution) into the common femoral
artery, according to the Seldinger technique. The catheter
tip was placed in the external carotid artery, under radio-
graphic control. Diagnostic transfemoral carotid arteriog-
raphy was performed and the most suitable branch of the
artery, providing the main blood supply to the tumour,
was selectively catheterised. The catheter was removed
immediately after the infusion. A simultaneous intrave-
nous (i.v.) infusion of 250 mL of 0,9% saline was per-
formed. Dexamethasone (4 mg) and ondansetron (1 g)
dissolved in 100 mL of 0,9% saline were administered i.v.
1 hour before the infusion. All patients received three
cycles of intra-arterial chemotherapy, administered every
two weeks. The planned dose of carboplatin per cycle was
300 mg/m2 for the first cohort (3 cases) and 325 mg/m2
for the second cohort (3 cases); subsequently, as no signif-
icant toxic effects were observed, the remaining patients
(40 cases) received a dose of 350 mg/m2 of carboplatin
per cycle. Two weeks after completing chemotherapy,
patients were restaged and subsequent treatment was
decided upon on the basis of their objective response.
Complete responders or partial responders had radiother-
apy; non-responders with resectable disease underwent
surgery on the tumor site and/or on the neck nodal metas-
tases followed by radiotherapy; non-responders with
unresectable disease underwent palliative radiotherapy.
Radiation was delivered using conventional fractionation
(1,8 – 2 Gy per fraction, five days per week). The total dose
was 66 – 70 Gy for PTVI (planning target volume includ-
ing tumour and encompassing all clinically positive
nodes) and 50–56 Gy for PTVII (planning target volume
including all anatomical regions at risk of subclinical
malignant disease).
Treatment evaluation
Toxicity was evaluated according to WHO criteria [13] 24
hrs after each drug administration. This included: assess-
ment of haematologic, hepatic and renal parameters;
assessment of gastrointestinal, otoneurological, cardiac
and respiratory function, and the search for signs and
symptoms of local toxicity. Response to therapy was
assessed two weeks after the last administration of the
drug by physical examination, endoscopy, imaging (CT
scan and/or MRI) and biopsy, when necessary. A complete
response (CR) was defined as the complete disappearance
of all demonstrable lesions. A partial response (PR) was
defined as a decrease of 50% or greater in the sum of the
products of the largest perpendicular diameters of all
measurable lesions. No response (NR) was defined as a
regression of < 50% in total tumour size or as stable or
progressive disease.
Statistical analysis
The primary efficacy end point was overall survival (i.e,
death as a result of any cause). Survival was measured
from the start of treatment date to the date of death or the
date when the patient was last known to be alive. Yearly
estimates were calculated using the Kaplan-Meier method.
Secondary efficacy end points were CR rates, loco-regional
tumour control and disease-free survival. Time to loco-
regional failure was measured from the start of treatment
date and the date of disease relapse, the date of disease-
related death, or the date when the patient was last known
to be alive and disease-free. Loco-regional failure, distant
Table 2: Pre-treatment tumour (T) and lymph node (N) staging
N0 N1 N2a N2b N2c N3 TOTAL
T2 84511 1 9
T3 95311 1 9
T4 14 21 8
TOTAL 1 8 1 3 8430 4 6BMC Cancer 2007, 7:62 http://www.biomedcentral.com/1471-2407/7/62
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metastases, or disease-related death were all considered
failures for disease-free survival. Yearly disease-free sur-
vival rates were estimated with the Kaplan-Meier method.
Factors influencing overall and disease-free survival were
analyzed and compared by the log-rank test. P values less
than 0.05 were considered significant.
Results
Feasibility
One hundred and thirty eight super-selective transfemoral
intra-arterial infusions of carboplatin were performed
with no significant complications.
Toxicity
Carboplatin treatment was well-tolerated by the majority
of the patients. No instances of gastrointestinal (nausea,
vomiting, diarrhoea), renal, cardiac, respiratory and
otoneurological toxicity were reported. Cases of systemic
and local toxicity are listed in table 3.
Response rate
After completing chemotherapy, 16 patients had a CR
(35%), 20 patients had a PR (43%) and 10 patients had
NR (22%). The 36 patients with a complete or partial
response underwent radiotherapy, after which 26 patients
achieved a complete response. Among the other 10
patients with persistent or recurrent disease in the neck, 5
underwent neck dissection and achieved a complete
response and 5 refused any further treatment. Seven of the
10 NR patients underwent neck and primary site surgery,
followed by radiotherapy. After this treatment, all 7
patients achieved a complete response. Of the remaining
3 non-responding patients, one refused any further treat-
ment and two had palliative radiotherapy. Upon complet-
ing all treatments, 38/46 patients (83%) achieved a
complete response: the 26 patients (CR) treated with
induction chemotherapy and radiotherapy; the 5 (PR)
treated with induction chemotherapy, radiotherapy and
neck surgery and the 7 (NR) treated with induction chem-
otherapy, primary site and neck surgery and radiotherapy.
(Fig. 1)
Control of disease and survival
No patients were lost to follow-up. The median follow-up
time, measured from the start of induction chemotherapy,
was 51.3 months (range: 5 to 136 months).
The current status of the patients is as follows: after com-
pleting the treatment protocol, the 8 patients with persist-
ent or recurrent disease (3 from the NR group and 5 from
the PR group) have died of the disease; 13 of the 38 CR
patients are alive and disease-free, 3 have died of distant
metastases (2 pulmonary and 1 hepatic) and 3 due to a
second primary tumour (2 lung cancers and 1 renal can-
Locoregional response after completion of treatment proto- col (CIA = intra-arterial chemotherapy; CR = complete  response; PR = partial response; NR = no response; RT =  radiotherapy; NS = neck surgery; NTS = primary and neck  surgery; PRT = palliative radiotherapy; No Tr = no treat- ment) Figure 1
Locoregional response after completion of treatment proto-
col (CIA = intra-arterial chemotherapy; CR = complete 
response; PR = partial response; NR = no response; RT = 
radiotherapy; NS = neck surgery; NTS = primary and neck 
surgery; PRT = palliative radiotherapy; No Tr = no treat-
ment).
46 patients
      CIA
16 CR     20 PR 10 NR
       36 RT 7 NTS+RT 2 PRT 1 No Tr
26 CR    10 PR
  5 NS 5 No Tr
26 CR 5 CR 7 CR
38 CR
Table 3: Toxicity from chemotherapy
Type of toxicity Grade N. of patients
Neutropenia 2 2
Thrombocytopenia 1 2
Hyperbilirubinemia 4 1
Peripheral neuropathy 3 1
Alopecia 1–3 1
Stomatitis 2–3 2
Skin rash 3 1BMC Cancer 2007, 7:62 http://www.biomedcentral.com/1471-2407/7/62
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cer), which occurred after a mean period of 29 months.
The tumour recurred in 19 patients after a mean period of
25 months; 9 on the neck and 10 at the primary site. Five
of the 9 patients with tumour recurrence on the neck
underwent neck dissection; of these 2 are still alive and
disease-free and 3 have died due to the persistence of the
tumour; the other 4 received systemic chemotherapy. Of
these 1 is alive and free of disease while 3 have died of the
disease. Of the 10 patients in whom tumours recurred at
the primary site, 5 underwent palliative systemic chemo-
therapy and died of the disease, 2 received only palliative
medical treatment and died of the disease and 3 under-
went salvage surgery. Of these, 2 are alive and disease-free
and 1 has died of pulmonary metastases. In conclusion,
after a 5-year follow-up, 18 patients (39%) are alive and
disease-free, 3 (6,5%) have died due to a second primary
tumour and 25 (54,5%) have died of the disease (Fig. 2).
The percentage of organ preservation was 83%, as 8 of the
46 patients underwent salvage surgery at the tumour site.
The probability of five-year overall survival was 50% (Fig.
3). The main factor influencing overall survival was the
response to induction chemotherapy: CR patients showed
statistically significant better survival rates compared to
PR or NR patients, even if 12 (40%) of these patients were
successfully submitted to salvage surgery (Fig. 4).
Five-year disease-free survival, calculated on the 38
patients who were free of disease after completing all
treatments, was 49,8% (Fig. 5). In this case, the main fac-
tor influencing disease recurrence or the appearance of
distant metastases was patients' neck status: patients with
no metastatic lymph-nodes or patients whose metastatic
lymph-nodes regressed completely after induction chem-
otherapy had a better disease-free survival rate than
patients with positive nodes who had a partial or no
response to chemotherapy (Fig. 6).
Discussion
Our present data confirmed the evidence that regional
chemotherapy by superselective transfemoral infusion of
high doses of platinum compounds is feasible and that,
with the cooperation of an experienced interventional
radiologist, can be easily reproduced in a multi-institu-
Overall survival according to the response to induction  chemotherapy (CR = complete response; PR = partial  response; NR = no response) Figure 4
Overall survival according to the response to induction 
chemotherapy (CR = complete response; PR = partial 
response; NR = no response).
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NR vs CR  p=0.03
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Clinical status of the patients at the end of follow-up (CR =  complete response; PR = partial response; NED = no evi- dence of disease; DWD = death due to disease; DSP = death  due to second primary tumour; NS = neck surgery; SS = sal- vage surgery; CT = systemic chemotherapy; PCT = palliative  systemic chemotherapy; No Tr = no treatment) Figure 2
Clinical status of the patients at the end of follow-up (CR = 
complete response; PR = partial response; NED = no evi-
dence of disease; DWD = death due to disease; DSP = death 
due to second primary tumour; NS = neck surgery; SS = sal-
vage surgery; CT = systemic chemotherapy; PCT = palliative 
systemic chemotherapy; No Tr = no treatment).
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tional setting, with minimal procedural complications
[9,11,14-16].
The advantage of carboplatin is that it has an antitumour
activity comparable with that of cisplatin but a toxicology
profile with lower renal and gastrointestinal effects
[10,17-19]. We administered far higher doses of carbopl-
atin than those used by Vieitez et al. [15], according to our
preliminary phase I study [20] that led us escalating the
cycle doses of carboplatin from 300 mg/m2 to 350 mg/
m2. These doses were comparable to the cisplatin "deca-
doses" used by Robbins et al. [21-24], without relying on
simultaneous i.v. treatment with sodium thiosulphate to
achieve systemic neutralisation of the platinum com-
pound.
Systemic toxicity was low in our study population: all
patients completed the three cycles of chemotherapy with
no chemotherapy-related deaths, only 4 cases of moderate
(grade 1–2) hematologic toxicity, and one case each of
high (grade 3–4) hepatic and neurological toxicity. Local
toxicity occurred in some cases, mainly at the level of skin
and oral mucosa, but of short duration and of low/mod-
erate degree. The higher systemic toxicity observed in
other studies based on the same intra-arterial chemother-
apy approach could be due to the different activity/toxic-
ity profile of cisplatin versus carboplatin or to the
potentiation of toxic effects in concurrent chemotherapy-
radiotherapy regimens.
With respect to a classic neoadjuvant intravenous chemo-
therapy protocol (Al Sarraf) our protocol presents the
advantage of a reduced systemic toxicity and of a reduced
duration (one day vs. three days administration, two
weeks vs. three weeks interval), with a significant
improvement of patient's compliance.
A true neoadjuvant intra-arterial chemotherapy approach
for head and neck cancer treatment is rare and the results
of many trials are difficult to compare, owing to a number
of methodological differences [16]. Limiting our compar-
ison to the latest studies conducted with platinum com-
pounds, our response rates at the end of induction
chemotherapy (CR 35% and PR 43%) are similar to those
observed by Kovacs [16] (CR 38% and PR 31%) and lower
than those observed by Wilson et al [25] (CR 68% and PR
23%).
Our five-year overall and disease-free survival rates (50%
and 49,8%) may be compared with those observed by
Kovacs [16] (77% and 59%). Even if concurrent chemora-
diation treatments seem to achieve the best overall sur-
vival rate [1], our results (50% and 49,8%) are similar to
those obtained with the RADPLAT protocol (38,8% and
53,6%) [26].
According to our previous results [11] and the opinion of
other authors [2,27], we consider the response to induc-
tion chemotherapy to be an important prognostic factor
which may determine the sequence and timing of further
planned definitive therapy: patients with a lesser response
will require total surgical resection of the disease or the
remaining disease, followed by post-surgical radiation
therapy; patients with a good response may avoid surgery
and be treated with radiotherapy alone. Therefore, on the
basis of the evaluation made after induction chemother-
apy, we adopted a flexible protocol, based not only on the
patient's compliance and general conditions, but mainly
on their response to neoadjuvant chemotherapy. A similar
but less customized multimodality treatment has been
followed by Kovacs et al. [28] in a large series of oral and
oropharyngeal cancer patients.
Conclusion
Our present experience suggests that in the treatment of
head and neck cancer, superselective intra-arterial infu-
Disease-free survival according to neck status (NO = no lym- phnodes at diagnosis; CR = complete response; PR = partial  response; NR = no response) Figure 6
Disease-free survival according to neck status (NO = no lym-
phnodes at diagnosis; CR = complete response; PR = partial 
response; NR = no response).
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sion with high doses of carboplatin delivered directly to
the tumour bed is a safe and well-tolerated technique with
no major systemic or local toxic side effects. It proves once
again that, compared to other protocols (e.g. concurrent
chemoradiotherapy), systemic or intra-arterial induction
chemotherapy, does not have a significant advantage in
terms of overall or disease-free survival. However, in some
patients with bulky head and neck tumours, this tech-
nique, adopted as part of a first-line multidisciplinary
approach, can achieve a high response rate, which may
have a prognostic significance. This is a prospective study
of a cohort of patients treated in a unique fashion in
which carboplatin was given as an intra-arterial infusion.
Those patients who had a major response were than
treated with radiation therapy only. Non-responders were
treated with surgery. The protocol introduces a novel algo-
rithm for management of patients with advanced head
and neck cancer. It is designed to triage patients who are
sensitive to chemotherapy to non-surgical regimen
whereas those who are not sensitive are treated with sur-
gery.
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